AstraZeneca (AZ, NASDAQ: AZN) Hong Kong has announced a partnership with Inocras Hong Kong Ltd and Cancerinformation.com.hk Charity Foundation (CICF) to launch the “HRDetect” program in Hong Kong and Macau. This initiative will provide eligible cancer patients in both regions with complimentary BRCA or HRD genetic testing. The genetic testing services will be conducted by Inocras’s laboratory based in San Diego.
Homologous recombination deficiency (HRD) arises from a defective DNA repair mechanism known as homologous recombination repair (HRR). Individuals with a BRCA germline mutation are identified as having an HRD deficiency. Recognizing HRD in patients with ovarian and certain other cancer types can be instrumental in guiding treatment strategies, particularly in the selection of targeted therapies such as PARP inhibitors (PARPi).- Flcube.com
